It’s high time to review my holdings and if anything changed in their investment thesis. This will be a monster post, for me it’s a great way to review all my holdings and make sure I stay up to date. For you, if you hold or are interested in one of these stocks you will get a quick “what’s the latest” with some sprinkles of why this is a great company (or not anymore). As a bonus there is a short elevator pitch of my two new holdings.
I stopped posting updates for every portfolio change (instead found under Trade History tab), so I have some changes to comment on: MIX Telematics left the portfolio and Lvji entered and exited without comment from my side. MIX Telematics was a case of having too high exposure to the oil industry in the US, I don’t see that coming back at all in the same way as in the past. This was something I did not understand when I invested, properly hidden oil exposure and a mistake on my side. Lvji was a tech play on travel guides for Chinese, but soon after taking a position some twitter friends alerted me of doubtful accounting. I looked at it myself and couldn’t really feel comfortable, better safe than sorry I then sold at almost the same price I bought.
Now on to comments on all my current holdings from top to bottom in the table below.
2019 has been the toughest year for the GlobalStockPicking portfolio in terms of under-performing against the MSCI World benchmark, YTD the return stand at 3% vs 15% for MSCI World. I did very well up until about April this year, when I posted about a new all time high for the portfolio. Such boasting was immediately punished with severe under-performance. Both US and European markets have performed well, whereas Asia is more in line with my portfolio. With quite a lot of Asia exposure the portfolio has fallen behind, but even taken that into account I have under-performed.
Obviously I’m disappointed, but more so I have been scratching my head. Is this how it should look like at a market peak, as irrational investors pile into Beyond Meat like investments and rational investors fall behind? Or am I on the wrong track and investing in poor value trap companies etc? Before going further into that topic, below is the return in a more digestible format:
Two portfolio “issues”
First “issue”, I’m sitting on a few Hong Kong small cap investments which are pretty much dead in the water. The market sentiment in Hong Kong currently is not very good and although my companies (thinking foremost of Tonly Electronics, Modern Dental Group and Dream International) seem to have little exposure to trade tariffs (for Dream it’s actually a positive) or exposure to Hong Kong protests, the stocks are not moving. These three holdings at 17% of my portfolio seem to be pretty much in value trap land at the moment. Sure they might be cheap, but there is no interest in the market to price these stocks at higher multiples. So is this an issue then? Well yes and no, if it’s important to keep measuring yourself against a benchmark which keeps moving upwards, then it is an issue. If you are long-term and the underlying businesses are doing all right, it’s a non-issue, at some point the market will wake up and revalue the companies. Given that I want to be very long term, I have decided that this is not an issue for me. Obviously that might change when the semi-annuals soon are released for this companies.
I’m having too many large cap companies in my portfolio where I have no reasonable edge against the market. Not having an edge on the market is something I thought a lot about lately and something I realized is critical for long term out-performance. I see two main cases (there might be others) where I think I could still have an edge in large caps:
That I have a much longer investment horizon than the market (my investment in Diageo, Inditex,, Essity, Dairy Farm and LG Chem are based on this).
Irrational selling flows in certain market segments, for example Hong Kong listed stocks right now, or stocks not fitting into the ESG portfolios which seems to go into everything right now (my investments in Swedish Match, BATS and Philip Morris are based on this).
Basically this gives me a few large cap holdings which have not really been bought with these “edges” in mind: NetEase, Gilead Science and partly NagaCorp. But NagaCorp being a Cambodian investment, listed in Hong Kong and after a big run-up trades around 6bn USD in MCAP. I would say it’s not really a main stream large cap investment just yet.
Portfolio Changes
Selling Gilead Science
Already back when I invested in Gilead I “confessed” that I had struggled to find a really great Pharma investment case. I relied heavily on other investors and their analysis when I invested in Gilead (Another Portfolio change Aug 2017). I think shows a bit how my investment style has changed since then. Today I would not do such an investment without doing my own due diligence a bit deeper first. Given the “no edge” argument, it’s time to let this one go and invest in something where I think I found an undervalued company, which the whole market is not aware of.
Selling British American Tobacco (BATS)
I might be right that ESG tilts in portfolios have put tobacco stocks on the no-go list of investments, but I can’t just base such a large portion of my portfolio just on this. I need to see that these companies long term are capable of delivering great returns in my portfolio. Swedish Match I think qualifies there, that’s why I increased my position there. Philip Morris might qualify long term, I do like the IQOS product and long term it’s success will be pretty crucial for delivering really strong shareholder returns. In BATS case, I’m pretty confident that this is a good defensive company which will deliver decent shareholder returns, if I was a corporate bond investor I would like BATS quite a lot. But I’m looking for slightly higher returns and I gambled a bit too much on this ESG angle having 3 tobacco companies in the portfolio, two is enough and BATS is the weakest link.
Selling Essity and switching into it’s subsidiary Vinda
This switch is something I haven’t mentioned, but looked at for a long time now. Vinda being a Chinese tissue paper products producer, majority owned by Essity and listed in Hong Kong. Basically the case is that given demographics, Vinda will see much stronger growth than the rest of Essity, which is also confirmed in historical results. So all else equal given higher growth Vinda should trade at a higher multiple, but it’s rather trading just in line with Essity. Why? Probably because Vinda being somewhat illiquid in comparison with a small float of some 25% on 2.2bn USD MCAP. But you get a Swedish governance run company, with full exposure to China’s growing middle-class and elderly population. This is truly something to put in the long term bucket.
Some pictures showing how Essity and Vinda traded since Essity got listed as a separate entity (spun out from SCA):
I was unfortunately asleep at the wheel during the summer when the spread was at it’s largest. The spread shrunk after great H1 results from Vinda, but has increased again on back of Hong Kong stocks under-performing in general (probably due to protests etc). So this gave me another opportunity to switch into Vinda.
Initiate new position in AK Medical Holdings
Another twitter inspired holding (LiveChat being the other), which I feel a bit ashamed of not having found myself (given how much time I spend looking for stocks on the HK exchange). Again my timing here is not the best given that the stock has rallied quite a lot recently. A full write-up will have to wait, but this is the holding I hinted at in my 3-D printing post. The company produces orthopedic implants, mainly for the hip and knees. The sell their products almost exclusively in China. Over the last few years the spent quite a lot of resources to use 3D-printing technology to create better custom made hip implants. Just as I wrote about in the 3D-printing post, the most successful examples of 3D-printing so far has been for the human body, where the need for customization is high. The companies sales of 3D-printed implant parts is still fairly small compared to total revenue, but it’s growing very nicely. It also shows the companies ambition to not just be the low cost option for implants compared to international players.
I think the company partly have traded so strong lately due to trade war speculation. If the trade war intensifies, probably international companies selling hip implants will face difficulties, which could favor a local player like AK Medical. My investment thesis is not based on this though, although of course it’s nice to have a trade war hedge in the portfolio.
This company is not trading at very cheap levels, so I will start with a fairly small position. You will have to wait a while longer for a full write-up.
Sizing and adding in Sbanken
I sell the full holdings in Gilead Science, BATS and Essity as of close Friday. This takes my cash level to about 14.1%. Of this I allocate a 5% to Vinda and a 3% position to AK Medical Holdings. Of the cash left I decided to increase my position in Sbanken again, which has traded down significantly on general Nordic bank stock weakness. I take my Sbanken position back to 5% of the portfolio, leaving a small cash buffer.
